Throxinyldimethylphosphinate was invented as a prodrug to stabilize thyroxine, a drug widely used to treat hypothyroidism. The presence of the dimethylphosphinate group at the phenolic hydroxyl of thyroxine is key to preventing thyroxine from decomposing through the proposed pathway. The prodrug will be hydrolyzed in the stomach or the gut into thyroxine and the biologically inert dimethylphosphinic acid. Related products may be stabilized with the same or similar protecting groups.
申请公布号
WO0135902(A2)
申请公布日期
2001.05.25
申请号
WO2000US31220
申请日期
2000.11.15
申请人
LOTUS BIOCHEMICAL CORPORATION;PICCARIELLO, THOMAS;LECLERCQ, ANNE, F.